ArticleVeterinary research communications2026
Investigating changes in serum metabolome and urinary endocrine disrupting chemicals in cats with hyperthyroidism.
Article in Veterinary research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Domestic cats share indoor environments with humans and are exposed to endocrine-disrupting chemicals (EDCs) from both household sources and cat-specific products capable of disrupting thyroid hormone signaling. The prevalence of feline hyperthyroidism (FHT) continues to rise, and while some EDCs have been implicated in its etiopathogenesis, the metabolic consequences of FHT are unknown. Here, we tested whether hyperthyroid cats exhibit altered systemic metabolomic signatures that are associated with phthalate and paraben urinary levels, compared with healthy controls. Thirty-five pet cats were enrolled (16 FHT, 19 controls). Serum samples were subjected to untargeted liquid chromatography mass spectrometry metabolomics and urine paraben and phthalates metabolites were quantified by liquid chromatography-tandem mass spectrometry. Forty-six serum metabolites and three urinary EDCs differed between groups (adjusted p < 0.05). Lipid metabolism pathways were enriched (16/74 significant; Fisher’s p = 0.02; False Discovery Rate-adjusted p = 0.16). Key serum differences included lower creatinine, linoleic acid, and 1-oleoyl-sn-glycerophosphoethanolamine in FHT. Urinary mono-isobutyl phthalate, ethylparaben, and propylparaben were higher in FHT (fold change 2.58, 3.30 and 2.07). Multivariable analyses separated groups; Weighted Sub-Network Analysis highlighted modules tied to tryptophan pathways, lipid homeostasis, and xenobiotic processing. Partial Least Squares captured 91% of response variance in two factors, with high-Variable Importance in Projection contributors including vitamin K1, 2-hydroxybenzothiazole, a sphingolipid long-chain base, and L-cysteine-glutathione disulfide. A Random Forest classifier achieved a 9.38% out-of-bag error and prioritized sphingoid bases and creatinine. Hyperthyroid cats had perturbed serum lipid-metabolite levels and higher urinary phthalate and paraben biomarker levels. These integrated data support an EDC-associated metabolomic signature in FHT and motivate longitudinal and mechanistic studies to clarify causality and inform prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.